CompanyHealthEnterprise
Quanta Therapeutics
Quanta Therapeutics is a clinical-stage biopharmaceutical company in South San Francisco building allosteric small-molecule inhibitors for RAS-driven cancers. Using a proprietary Second Harmonic Generation (SHG) optical platform that detects subtle changes in protein conformation, Quanta designs oral drugs aimed at KRAS mutations long considered undruggable - including G12D and G12V - that together drive a large share of pancreatic, colorectal, lung and endometrial cancers. Its lead candidate QTX3034 is in Phase 1 trials, with QTX3544 and a pan-KRAS program close behind.
2018Founded
South San FranciscoHQ
$60 millionSeries C
kras inhibitorsras-driven cancersoncologyallosteric drug discoverysecond harmonic generationshg technology